Elbonix 25 mg | Generic Eltrombopag by Beacon Pharmaceuticals

Description

Dr. Daria Kwaśniewska ESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist or haematologist prescription is mandatory before any order is processed. Eltrombopag is not approved for dengue-related thrombocytopenia — never use this medication outside its approved indications without explicit physician guidance.

Is Elbonix 25 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓Chronic immune thrombocytopenia (ITP) with inadequate response to corticosteroids, immunoglobulins, or splenectomy
✓Thrombocytopenia associated with chronic hepatitis C, to permit initiation/maintenance of interferon-based therapy
✓Severe aplastic anaemia, as first-line therapy with immunosuppression or as refractory-disease treatment
✓Need a WHO-GMP generic alternative to Promacta®/Revolade® (Novartis/GSK)

✖ May NOT be suitable if

✗Thrombocytopenia from dengue, viral infection, or other non-approved causes — not an approved indication
✗Significant pre-existing liver impairment without close monitoring capability
✗History of arterial or venous thromboembolism
✗Pregnant, planning pregnancy, or breastfeeding

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Elbonix 25 mg?

Elbonix 25 mg is a generic formulation of Eltrombopag — an oral thrombopoietin (TPO) receptor agonist — manufactured by Beacon Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 25 mg of eltrombopag, the same active molecule found in Promacta® (Novartis, US) / Revolade® (GSK, international), and is dispensed under the Named Patient Program for patients requiring an affordable, quality-assured alternative.

Eltrombopag works by stimulating the bone marrow to increase platelet production — it is a targeted treatment for specific, confirmed conditions of low platelet count, not a general-purpose platelet booster for any cause of thrombocytopenia.

Generic name	Eltrombopag
Reference brand	Promacta® / Revolade® (Novartis / GSK)
Manufacturer	Beacon Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	Thrombopoietin (TPO) Receptor Agonist
Dosage form	Tablet — 25 mg (also available 50 mg)
Pack size	28 tablets per pack
Route	Oral · once daily, fasting, away from dairy
Prescription	Required — oncologist/haematologist only

How Eltrombopag Works

Platelets are produced by bone marrow cells called megakaryocytes, a process regulated by a natural hormone called thrombopoietin (TPO). In conditions like ITP, aplastic anaemia, and hepatitis-C-associated thrombocytopenia, platelet production or survival is impaired, leading to dangerously low counts and bleeding risk.

Eltrombopag binds to and activates the TPO receptor on megakaryocyte precursor cells, stimulating their proliferation and differentiation — increasing platelet production through the body’s own natural pathway, rather than through immunosuppression or transfusion. This mechanism is specific to conditions where the bone marrow retains the capacity to respond to TPO stimulation, which is why eltrombopag is approved only for specific, confirmed diagnoses rather than thrombocytopenia from any cause. View NCCN Clinical Guidelines →

What to Expect: First 30 Days

Response to eltrombopag is gradual — platelet counts typically begin rising within 1–2 weeks, with the dose adjusted based on response over the following weeks.

Week 1: Baseline liver function tests are required before starting. Your doctor will confirm the correct starting dose for your specific indication and ethnicity (East/Southeast Asian patients require a lower starting dose).
Weeks 2–3: Platelet counts are checked weekly initially. Dose adjustments (up or down) are made based on the platelet response — the goal is the lowest effective dose to minimise bleeding risk without overshooting into dangerously high counts.
Week 4: Liver function tests are repeated. If a stable, safe platelet count is reached, monitoring frequency typically reduces, but periodic blood tests continue throughout treatment.

Side Effects

Eltrombopag carries important warnings around liver toxicity and blood clot risk that require ongoing monitoring throughout treatment.

Common · Usually Manageable

Headache
Nausea or diarrhoea
Fatigue
Muscle or joint pain
Mouth/throat irritation
Hair thinning
Mild rash

Serious · Report Immediately

Hepatotoxicity (liver injury)
Thrombotic/thromboembolic events (blood clots)
Excessive platelet response (thrombocytosis)
New or worsening cataracts
Increased bone marrow reticulin (rare)

⚠ Call your doctor immediately if you experience:

Yellowing of skin or eyes, dark urine, or unusual fatigue (possible liver injury)
Sudden leg swelling/pain, chest pain, or breathlessness (possible blood clot)
Cloudy or blurry vision changes

How to Take Elbonix 25 mg

Standard dose varies significantly by indication — ITP: 50 mg once daily (starting dose, adjusted by response) · Hepatitis-C-associated thrombocytopenia: 25 mg once daily starting dose · Severe aplastic anaemia (first-line): 150 mg once daily · Refractory aplastic anaemia: 50 mg once daily starting dose. Always follow your prescribed dose exactly — do not self-adjust.

1
Take on an empty stomach — at least 1 hour before or 2 hours after eating, for consistent and predictable absorption.
2
Avoid dairy products, antacids, and mineral supplements within 4 hours of your dose — calcium and other polyvalent cations (iron, calcium, aluminium, magnesium, selenium, zinc) significantly reduce eltrombopag absorption.
3
Swallow tablets whole with water. Do not chew or crush.
4
If you miss a dose, do not double up — resume your normal schedule at the next dose.
5
Storage: at room temperature, away from moisture, light, and out of reach of children.

Caregiver Guidance

♥
Help manage the empty-stomach timing — this medication’s absorption is significantly affected by food and especially dairy/calcium-containing products. Plan meals and supplements around the dosing schedule carefully.
♥
Watch for jaundice or unusual fatigue — liver function is monitored regularly, but new yellowing of skin/eyes or unexplained fatigue between tests should be reported immediately.
♥
Track scheduled blood tests — platelet counts and liver function tests guide every dose adjustment. Missing appointments delays safe, effective dosing.

If the Medicine Stops Working

If platelet counts fail to respond adequately after 2–3 weeks at the maximum approved dose, your doctor will typically discontinue eltrombopag rather than continue an ineffective treatment, since prolonged use without adequate response provides no benefit while maintaining risk. For ITP, alternative strategies may include a different TPO receptor agonist, rituximab, or other second-line immunomodulatory therapies. For aplastic anaemia, intensified immunosuppression or stem cell transplant evaluation may be considered depending on disease severity and donor availability.

Frequently Asked Questions

Can Elbonix be used to treat low platelets from dengue fever?

No. Eltrombopag is not FDA-approved or clinically established for dengue-related thrombocytopenia. Its approved indications are chronic ITP, hepatitis-C-associated thrombocytopenia, and severe aplastic anaemia — all conditions with a different underlying mechanism than dengue-related platelet drops. Using eltrombopag outside its approved indications without direct physician guidance is not recommended and could carry unknown risks. Dengue-related thrombocytopenia should be managed according to your treating physician’s specific protocol.

Why does the dose vary so much between conditions?

Eltrombopag dosing is indication-specific because the underlying disease mechanisms and target platelet responses differ. ITP typically starts at 50 mg, hepatitis-C-associated thrombocytopenia starts lower at 25 mg (often alongside antiviral therapy), and severe aplastic anaemia uses a much higher starting dose of 150 mg because the bone marrow failure is more severe. Never apply one indication’s dose to another condition.

Why can’t I take this with dairy or calcium supplements?

Eltrombopag binds (chelates) with polyvalent cations including calcium, iron, magnesium, aluminium, selenium, and zinc — commonly found in dairy products, antacids, and mineral supplements. This binding significantly reduces drug absorption, potentially making the medication less effective. Separate dosing from these products by at least 4 hours.

What monitoring do I need while taking Elbonix?

Liver function tests are required before starting and periodically during treatment due to hepatotoxicity risk. Platelet counts are monitored weekly initially, then less frequently once a stable dose is established. Eye examinations may be recommended periodically due to a rare association with cataract changes.

Will I need a lower starting dose if I am of East or Southeast Asian heritage?

Yes, in most indications. Eltrombopag plasma exposure is significantly higher (approximately 70–80%) in East Asian and Southeast Asian patients compared to other populations, so a reduced starting dose is typically recommended for ITP and severe aplastic anaemia (though not for hepatitis-C-associated thrombocytopenia). Your oncologist or haematologist will determine the appropriate starting dose for your background.

How do I order Elbonix through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist or haematologist’s prescription specifying your diagnosis and prescribed dose. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid oncologist prescription, in countries where the branded product is unavailable or unaffordable.

This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.

Clinical References

Bussel JB, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. NEJM 2007;357:2237–2247.
Townsley DM, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. NEJM 2017;376:1540–1550.
FDA Prescribing Information: Promacta (eltrombopag). Novartis, 2023.
McHutchison JG, et al. Eltrombopag for thrombocytopenia in patients with hepatitis C. NEJM 2007;357:2227–2236.